Clinical Trial Update: Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 clinical trial evaluating omega-3 fatty acid deficiency replacement in early schizophrenia, sponsored by the University of Cincinnat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Omega-3 Fatty Acid Deficiency Replacement (Omega-3 fatty acids)

Snippet

Sponsor: University of Cincinnati | Conditions: Schizophrenia, Fatty Acid Deficiency | Phase 2, Phase 3 | Status: COMPLETED